Lecture 31 Word Scramble
T I E A A M R H R T L I O
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
| Question | Answer |
| What type of clot is platelet rich and white in appearance? | Aterial thromi |
| What is the suggested evaluation for arterial thrombosis? | 1)Lupus anticoagulant and anticardiolipin Ab 2)Homocysteine level 3)Lipid levels 4)Rule out estrogen and vasculitic risk factors |
| Approximately what percentage of proximal DVTs are associated with pulmonary embolism? | Approximately 50% |
| Why does aPTT need to be standarized before comparing from different clinical laboratories? | 1)aPTT reagents differ in phospholipid content and contact activators 2)aPTT and heparin levels may be discordant due to effects of plasma proteins |
| How are the anticoagulant effects monitored by LMWH? | Anti-Xa assay |
| How is Lepirudin administered? | IV |
| What is the half-life of warfarin? | 36-42 hours |
| What is the half-life of Argatroban? | 39-51 mins |
| How is Lepirudin excreted? | Renally |
| What are the accepted indications for thromboytic therapy? | 1)Acute myocardial infarctions 2)Acute peripheral arterial occlusive disease 3)Massive pulmonary embolism associated with hemodynamic instability |
| What is the mechanism of Argatroban? | Reversible Direct Thrombin (FIIa) Inhibitor |
| How is Bivalirudin administered? | IV |
| What are the clinical criteria for Antiphospholipid syndrome? | 1)Vascular thrombosis (artieral or venous) 2)Pregnancy complicatons |
| What are the antiphospholipid antibodies? | 1)Lupus anticoagulant 2)Prothrombin antibodies 3)Anti-cardiolipin antibodies 4)B2 Glycoprotein 1 antibodies |
| How is LMWH administered? | SQ |
| What is the appearance of an extremitiy with an arterial thrombosis? | Extremities are blue, cold, and pulseless. |
| What pharmacologic agents are indirect Factor Xa Inhibitors? | 1)Heparin 2)Low Molecular Weight Heparin 3)Fondaparinux |
| What is the half-life of Bivalirudin? | 25 mins |
| How is heparin administered? | IV or SQ |
| How is Bivalirudin excreted? | Renally |
| What are the laboratory criteria for Antiphospholipid syndrome? | 1)Anti-cardiolipin Antibody (IgG or IgM) 2) Positive Lupus anticoagulant assay |
| What is the mechanism of Lepirudin? | Irreversible Direct Thrombin (IIa) Inhibitors |
| How is fondaparinux excreted? | Renally |
| How is LMWH excreted? | Renally |
| (T or F) Methylene tetrahydrofolate reductase results in primary elevated homocysteine levels. | True. |
| (T or F) LMWH is fully reversible with protamine. | False. LMWH is only partially reversible with protamine. |
| How is fondaparinux administered? | SQ |
| What pharmalogical agent reverses the effects of heparin? | Protamine |
| What is the half-life of Lepirudin? | 1.5 hours |
| What is the half-life of LMWH? | 4-6 hours |
| Factor Xa to Factor IIa activity of unfractionated heparin vs. low molecular weight heparin | UFH= 1:1 vs. LMWH 4:1 - 2:1 (LMWH have less than 19 saccharide units therefore they lack thrombin inhibition) |
| What is the half-life of heparin? | Varies by dose (average is 1-2 hours) |
| Are the anticoagulant effects of Lepirudin reversible? | No |
| What is the half-life of Fondaparinux (Arixtra)? | 15-18 hours |
| Are the anticoagulant effects of Bivalirudin reversible? | No |
| What is the suggested evaluation for venous thromboembolism in a patient with no previous family or personal history? | 1)Lupus anticoagulant and anticardiolipin Ab 2)Homocysteine level 3)Consider Factor V Leiden, Factor II mutation, Factor VIII level, Fibrinogen studies 3)Rule out estrogen and vasculitic risk factors |
| How is Argatroban excreted? | Metabolized by the liver |
| What are the complications of warfarin therapy? | 1)Bleeding 2)Warfarin induced skin necrosis 3)Cholestatic jaundice 4)Nausea/vomiting 5)Alopecia 6)Mouth ulcers 7)Rash |
| How is Argatroban administered? | IV |
| Are the anticoagulant effects of Argatroban reversible? | No |
| What are the contraindications to thrombolytic therapy? | 1)Major internal bleeding in the last 6 mo 2)Intracranial or intraspinal disease 3)Operation or biopsy in the preceding 10 days 4)HTN (sys >200, dia>110) 5)Active endocarditis 6)Pericarditis 7)Aneurysm 8)Presence of bleeding disorder |
| What are the advantages of LMWH? | 1)Better predictability of anticoagulant effect at a given dose;therefore, less need for lab monitoring 2)Longer plasma half-life 3)Less effect on the hemostatic properties of the endothelium and platelets perhaps accounting for less hemorrhagic potential |
| Are the anticoagulant effects of fondaparinux reversible? | No |
| (T or F) LMWH never need monitoring. | False. Patients with changing or decreased kidney function must be monitored. Also, very large or very small and pregnant patients may need dose adjustments |
| What is the mechanism of Bivalirudin? | Reversible Direct Thrombin(IIa) Inhibitors |
| How are the anticoagulant effects monitored by fondaparinux (Arixtra)? | Anti-Xa assay |
Created by:
UVAPATH4
Popular Medical sets